

# Carolina Barnett

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/260996/publications.pdf>

Version: 2024-02-01

94  
papers

1,840  
citations

279487

23  
h-index

329751

37  
g-index

99  
all docs

99  
docs citations

99  
times ranked

1598  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rituximab as treatment for anti-MuSK myasthenia gravis. <i>Neurology</i> , 2017, 89, 1069-1077.	1.5	185
2	Clinical Measures of Bulbar Dysfunction in ALS. <i>Frontiers in Neurology</i> , 2019, 10, 106.	1.1	95
3	Epidemiology of myasthenia gravis in Ontario, Canada. <i>Neuromuscular Disorders</i> , 2016, 26, 41-46.	0.3	90
4	International clinimetric evaluation of the MGâ€QOL15, resulting in slight revision and subsequent validation of the MGâ€QOL15r. <i>Muscle and Nerve</i> , 2016, 54, 1015-1022.	1.0	85
5	Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis. <i>Muscle and Nerve</i> , 2019, 59, 404-410.	1.0	56
6	Novel Treatments in Myasthenia Gravis. <i>Frontiers in Neurology</i> , 2020, 11, 538.	1.1	54
7	Measuring Clinical Treatment Response in Myasthenia Gravis. <i>Neurologic Clinics</i> , 2018, 36, 339-353.	0.8	51
8	Minimal clinically important difference in myasthenia gravis: Outcomes from a randomized trial. <i>Muscle and Nerve</i> , 2014, 49, 661-665.	1.0	50
9	The Quantitative Myasthenia Gravis Score. <i>Journal of Clinical Neuromuscular Disease</i> , 2012, 13, 201-205.	0.3	46
10	Development and validation of the Myasthenia Gravis Impairment Index. <i>Neurology</i> , 2016, 87, 879-886.	1.5	43
11	Incat disability score: A critical analysis of its measurement properties. <i>Muscle and Nerve</i> , 2014, 50, 164-169.	1.0	41
12	Sex differences in neuropathic pain intensity in diabetes. <i>Journal of the Neurological Sciences</i> , 2018, 388, 103-106.	0.3	38
13	Myasthenia Gravis Impairment Index. <i>Neurology</i> , 2017, 89, 2357-2364.	1.5	35
14	Fatigue is a relevant outcome in patients with myasthenia gravis. <i>Muscle and Nerve</i> , 2018, 58, 197-203.	1.0	33
15	Patient-acceptable symptom states in myasthenia gravis. <i>Neurology</i> , 2020, 95, e1617-e1628.	1.5	33
16	Laser Doppler Flare Imaging and Quantitative Thermal Thresholds Testing Performance in Small and Mixed Fiber Neuropathies. <i>PLoS ONE</i> , 2016, 11, e0165731.	1.1	33
17	Intravenous immunoglobulin as treatment for myasthenia gravis: current evidence and outcomes. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1659-1665.	1.3	31
18	The Characteristics of Chronic Inflammatory Demyelinating Polyneuropathy in Patients with and without Diabetes â€“ An Observational Study. <i>PLoS ONE</i> , 2014, 9, e89344.	1.1	29

#	ARTICLE	IF	CITATIONS
19	Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 94-97.	0.9	28
20	Repetitive nerve stimulation cutoff values for the diagnosis of myasthenia gravis. <i>Muscle and Nerve</i> , 2017, 55, 166-170.	1.0	27
21	The utility of a single simple question in the evaluation of patients with myasthenia gravis. <i>Muscle and Nerve</i> , 2018, 57, 240-244.	1.0	27
22	Chronic immunoglobulin maintenance therapy in myasthenia gravis. <i>European Journal of Neurology</i> , 2021, 28, 639-646.	1.7	27
23	Thymectomy for non-thymomatous myasthenia gravis: a propensity score matched study. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 214.	1.2	26
24	Reliability and validity of speech & pause measures during passage reading in ALS. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 42-50.	1.1	26
25	Toronto Clinical Neuropathy Score is valid for a wide spectrum of polyneuropathies. <i>European Journal of Neurology</i> , 2018, 25, 484-490.	1.7	23
26	Serious infections in patients with myasthenia gravis: population-based cohort study. <i>European Journal of Neurology</i> , 2020, 27, 702-708.	1.7	23
27	A Conceptual Framework for Evaluating Impairments in Myasthenia Gravis. <i>PLoS ONE</i> , 2014, 9, e98089.	1.1	23
28	IVIg and PLEX in the treatment of myasthenia gravis. <i>Annals of the New York Academy of Sciences</i> , 2012, 1275, 1-6.	1.8	21
29	Prevalence of Muscle Cramps in Patients With Diabetes: Table 1. <i>Diabetes Care</i> , 2014, 37, e17-e18.	4.3	21
30	Canadian Administrative Health Data Can Identify Patients with Myasthenia Gravis. <i>Neuroepidemiology</i> , 2015, 44, 108-113.	1.1	20
31	Current pharmacotherapeutic options for myasthenia gravis. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 2295-2303.	0.9	20
32	Electrophysiological testing is correlated with myasthenia gravis severity. <i>Muscle and Nerve</i> , 2017, 56, 445-448.	1.0	19
33	Predictors of response to immunomodulation in patients with myasthenia gravis. <i>Muscle and Nerve</i> , 2012, 45, 648-652.	1.0	18
34	Performance of individual items of the quantitative myasthenia gravis score. <i>Neuromuscular Disorders</i> , 2013, 23, 413-417.	0.3	18
35	Frequent laboratory abnormalities in CIDP patients. <i>Muscle and Nerve</i> , 2016, 53, 862-865.	1.0	18
36	Quality of life in patients with neurofibromatosis type 1 and 2 in Canada. <i>Neuro-Oncology Advances</i> , 2020, 2, i141-i149.	0.4	18

#	ARTICLE	IF	CITATIONS
37	Construction and validation of the chronic acquired polyneuropathy patient-reported index (CAP-EPRI): A disease-specific, health-related quality-of-life instrument. <i>Muscle and Nerve</i> , 2016, 54, 9-17.	1.0	17
38	Sural-to-radial amplitude ratio in the diagnosis of diabetic sensorimotor polyneuropathy. <i>Muscle and Nerve</i> , 2012, 45, 126-127.	1.0	15
39	Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis. <i>Muscle and Nerve</i> , 2016, 53, 872-876.	1.0	14
40	Chronic stress, depression and personality type in patients with myasthenia gravis. <i>European Journal of Neurology</i> , 2020, 27, 204-209.	1.7	14
41	Clinical characteristics, and impairment and disability scale scores for different CIDP Disease Activity Status classes. <i>Journal of the Neurological Sciences</i> , 2017, 372, 223-227.	0.3	13
42	Characterizing the ASD-ADHD phenotype: measurement structure and invariance in a clinical sample. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2022, 63, 1534-1543.	3.1	13
43	Effects of napping on neuromuscular fatigue in myasthenia gravis. <i>Muscle and Nerve</i> , 2013, 48, 816-818.	1.0	12
44	Uric acid levels correlate with the severity of diabetic sensorimotor polyneuropathy. <i>Journal of the Neurological Sciences</i> , 2017, 379, 94-98.	0.3	12
45	EQ-5D-5L and SF-6D health utility index scores in patients with myasthenia gravis. <i>European Journal of Neurology</i> , 2019, 26, 452-459.	1.7	12
46	Psychometric Properties of the Quantitative Myasthenia Gravis Score and the Myasthenia Gravis Composite Scale. <i>Journal of Neuromuscular Diseases</i> , 2015, 2, 301-311.	1.1	11
47	Disease activity in chronic inflammatory demyelinating polyneuropathy. <i>Journal of the Neurological Sciences</i> , 2016, 369, 204-209.	0.3	11
48	Comparison of the single simple question and the patient acceptable symptom state in myasthenia gravis. <i>European Journal of Neurology</i> , 2020, 27, 2286-2291.	1.7	11
49	Thymoma pathology and myasthenia gravis outcomes. <i>Muscle and Nerve</i> , 2021, 63, 868-873.	1.0	11
50	Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials. <i>Neurology</i> , 2021, 97, S50-S63.	1.5	11
51	Association of social support with quality of life in patients with polyneuropathy. <i>Journal of the Peripheral Nervous System</i> , 2013, 18, 37-43.	1.4	10
52	Retrospective study on the safety of COVID-19 vaccination in myasthenia gravis. <i>Muscle and Nerve</i> , 2022, 66, 558-561.	1.0	10
53	Evidence of small-fiber neuropathy in neurofibromatosis type 1. <i>Muscle and Nerve</i> , 2019, 60, 673-678.	1.0	9
54	Preliminary Findings of a Dedicated Ocular Myasthenia Gravis Rating Scale: The OMGRate. <i>Neuro-Ophthalmology</i> , 2020, 44, 148-156.	0.4	9

#	ARTICLE	IF	CITATIONS
55	Prospective study of stress, depression and personality in myasthenia gravis relapses. BMC Neurology, 2020, 20, 261.	0.8	9
56	Performance of different criteria for refractory myasthenia gravis. European Journal of Neurology, 2021, 28, 1375-1384.	1.7	9
57	Telephone consultation for myasthenia gravis care during the COVID 19 pandemic: Assessment of a novel virtual myasthenia gravis index. Muscle and Nerve, 2021, 63, 831-836.	1.0	9
58	Treatment Responsiveness in CIDP Patients with Diabetes Is Associated with Higher Degrees of Demyelination. PLoS ONE, 2015, 10, e0139674.	1.1	9
59	Elevated Vibration Perception Thresholds in CIDP Patients Indicate More Severe Neuropathy and Lower Treatment Response Rates. PLoS ONE, 2015, 10, e0139689.	1.1	8
60	Cramps frequency and severity are correlated with small and large nerve fiber measures in type 1 diabetes. Clinical Neurophysiology, 2018, 129, 122-126.	0.7	8
61	New insights into very-late-onset myasthenia gravis. Nature Reviews Neurology, 2020, 16, 299-300.	4.9	8
62	Myasthenia Gravis Impairment Index: Sensitivity for Change in Generalized Muscle Weakness. Journal of Neuromuscular Diseases, 2020, 7, 297-300.	1.1	8
63	Excessive Daytime Sleepiness in Patients with Myasthenia Gravis. Journal of Neuromuscular Diseases, 2015, 2, 93-97.	1.1	7
64	The median to ulnar cross-sectional surface area ratio in carpal tunnel syndrome. Clinical Neurophysiology, 2018, 129, 2239-2244.	0.7	7
65	Myasthenia Gravis and Pregnancy: Toronto Specialty Center Experience. Canadian Journal of Neurological Sciences, 2021, , 1-5.	0.3	7
66	Validation of Articulatory Rate and Imprecision Judgments in Speech of Individuals With Amyotrophic Lateral Sclerosis. American Journal of Speech-Language Pathology, 2021, 30, 137-149.	0.9	7
67	Quantitative sonographic assessment of myotonia. Muscle and Nerve, 2018, 57, 146-149.	1.0	7
68	Validating Automatic Diadochokinesis Analysis Methods Across Dysarthria Severity and Syllable Task in Amyotrophic Lateral Sclerosis. Journal of Speech, Language, and Hearing Research, 2022, 65, 940-953.	0.7	7
69	Choosing drugs for the treatment of diabetic neuropathy. Expert Opinion on Pharmacotherapy, 2015, 16, 1805-1814.	0.9	6
70	Repetitive facial nerve stimulation in myasthenia gravis 1min after muscle activation is inferior to testing a second muscle at rest. Clinical Neurophysiology, 2016, 127, 3294-3297.	0.7	6
71	Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy. Neurology, 2018, 90, e2034-e2041.	1.5	6
72	Gelsolin Familial Amyloidosis Peripheral Neuropathy in Canada: A Case Report. Canadian Journal of Neurological Sciences, 2015, 42, 353-355.	0.3	5

#	ARTICLE	IF	CITATIONS
73	Neurofibromatosis Clinic: A Report on Patient Demographics and Evaluation of the Clinic. Canadian Journal of Neurological Sciences, 2017, 44, 577-588.	0.3	5
74	Recording Fewer Than 20 Potential Pairs With SFEMG May Suffice for the Diagnosis of Myasthenia Gravis. Journal of Clinical Neurophysiology, 2017, 34, 408-412.	0.9	5
75	Nerve function varies with hemoglobin A1c in controls and type 2 diabetes. Journal of Diabetes and Its Complications, 2018, 32, 424-428.	1.2	5
76	Effectiveness of Diagnostic Strategies in Suspected Delayed Cerebral Ischemia. Stroke, 2015, 46, 77-83.	1.0	4
77	Qualitative, Patient-Centered Assessment of Muscle Cramp Impact and Severity. Canadian Journal of Neurological Sciences, 2019, 46, 735-741.	0.3	4
78	A cross-sectional study of gender differences in quality of life domains in patients with neurofibromatosis type 1. Orphanet Journal of Rare Diseases, 2022, 17, 40.	1.2	4
79	Fcγ3 Receptor Polymorphisms Do Not Predict Response to Intravenous Immunoglobulin in Myasthenia Gravis. Journal of Clinical Neuromuscular Disease, 2012, 14, 1-6.	0.3	3
80	Laboratory Abnormalities in Polyneuropathy and Electrophysiological Correlations. Canadian Journal of Neurological Sciences, 2018, 45, 346-349.	0.3	3
81	Homonymous Retinal Ganglion Cell Layer Atrophy With Asymptomatic Optic Tract Glioma in Neurofibromatosis Type I. Frontiers in Neurology, 2020, 11, 256.	1.1	3
82	Occurrence of Amyotrophic Lateral Sclerosis in Type 1 Gaucher Disease. Neurology: Genetics, 2021, 7, e600.	0.9	3
83	Efficacy and safety of high infusion rate IVIG in CIDP. Muscle and Nerve, 2020, 62, 637-641.	1.0	2
84	Fracture Risk in Patients with Myasthenia Gravis: A Population-Based Cohort Study. Journal of Neuromuscular Diseases, 2021, 8, 625-632.	1.1	2
85	Chronic Inflammatory Demyelinating Polyneuropathy in Diabetes Patients. US Neurology, 2015, 11, 47.	0.2	2
86	Protocol for psychometric evaluation of the Amyotrophic Lateral Sclerosis - Bulbar Dysfunction Index (ALS-BDI): a prospective longitudinal study. BMJ Open, 2022, 12, e060102.	0.8	2
87	An update on the use of immunoglobulins as treatment for myasthenia gravis. Expert Review of Clinical Immunology, 2022, 18, 703-715.	1.3	2
88	Evidence of persistent improvements with long-term subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Muscle and Nerve, 2019, 60, 643-644.	1.0	1
89	Ultrasound in Multifocal Motor Neuropathy: Clinical and Electrophysiological Correlations. Journal of Clinical Neuromuscular Disease, 2019, 20, 165-172.	0.3	1
90	People With Myasthenia Are Getting Better, But Are They Doing Well?. Neurology, 2021, , 10.1212/WNL.00000000000012617.	1.5	1

#	ARTICLE	IF	CITATIONS
91	Excessive Daytime Sleepiness in Patients with Myasthenia Gravis. <i>Journal of Neuromuscular Diseases</i> , 2015, 2, 93-97.	1.1	1
92	Temporal Dispersion and Duration of the Distal Compound Muscle Action Potential Do Not Distinguish Diabetic Sensorimotor Polyneuropathy From Chronic Inflammatory Demyelinating Polyneuropathy. <i>Frontiers in Neurology</i> , 2022, 13, 872762.	1.1	1
93	High frequency of MGUS in DSP. <i>Muscle and Nerve</i> , 2018, 57, 1018-1021.	1.0	0
94	Validation of the Italian version of the Myasthenia Gravis Impairment Index (MGII). <i>Neurological Sciences</i> , 2021, , 1.	0.9	0